FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Padagis US Trospium Chloride Extended-Release Capsules Recall

Trospium Chloride Extended-Release Capsules, 60 mg, 30 Capsules per bottle, Rx Only, Ma…

Padagis US LLC · Minneapolis, MN

Risk level
Class II
Reported by FDA
Dec 13, 2023
Recall ID
D-0139-2024
Check your lot numberHow we source this data

Summary

Padagis US recalled Trospium Chloride Extended-Release Capsules starting Nov 1, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0139-2024 on Dec 13, 2023. Reason: Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules. Status: Ongoing.

Why it was recalled

Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules

Product description

Trospium Chloride Extended-Release Capsules, 60 mg, 30 Capsules per bottle, Rx Only, Manufactured By: Sidmak Laboratories (India) Pvt. Ltd. Plot No. 20, Pharmacity, Selaqui Industrial Area, Dehradun-248 197 Uttarakhand, India Distributed By: Padagis, Allegan, MI 49010. NDC: 0574-0118-30

Lot numbers, UPCs & expiration codes

Lot: 231104, 231105, 231106, exp 7/31/2025

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0139-2024
Classification
Class II
Status
Ongoing
Recall initiated
Nov 1, 2023
FDA report date
Dec 13, 2023
Quantity
7,032 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Padagis US LLC

Original FDA data

Every field from FDA enforcement report D-0139-2024, exactly as published.

Show all FDA fields
City
Minneapolis
State
MN
Status
Ongoing
Country
United States
Event ID
93345
Address
3940 Quebec Ave N
Code information
Lot: 231104, 231105, 231106, exp 7/31/2025
Postal code
55427-1244
Report date
Dec 13, 2023
Product type
Drugs
Recall number
D-0139-2024
Classification
Class II
Recalling firm
Padagis US LLC
Product quantity
7,032 bottles
Reason for recall
Failed Tablets/Capsules specifications; missing/broken/extra tablets within the capsules
Voluntary / mandated
Voluntary: Firm initiated
Product description
Trospium Chloride Extended-Release Capsules, 60 mg, 30 Capsules per bottle, Rx Only, Manufactured By: Sidmak Laboratories (India) Pvt. Ltd. Plot No. 20, Pharmacity, Selaqui Industrial Area, Dehradun-248 197 Uttarakhand, India Distributed By: Padagis, Allegan, MI 49010. NDC: 0574-0118-30
Distribution pattern
Nationwide in the USA
Recall initiation date
Nov 1, 2023
Initial firm notification
Letter
Center classification date
Dec 5, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0139-2024, published Dec 13, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls